Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07688148 |
| Title | A First-in-human Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of TAX2 in Patients With Relapsed/Refractory Advanced/Metastatic Solid Tumours (APM-CT001) |
| Acronym | APM-CT001 |
| Recruitment | Not yet recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | Apmonia Therapeutics |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | FRA | BEL |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Institut Jules Bordet | Brussels | 1070 | Belgium | Details | ||
| Universitair Ziekenhuis Gent | Ghent | 9000 | Belgium | Details | ||
| Centre Léon Bérard | Lyon | 69000 | France | Details | ||
| Institut Gustave Roussy | Villejuif | 94800 | France | Details |